CODX trades 2236.4% below Wall Street's consensus target of $6.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CODX achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Co-Diagnostics, Inc. (CODX) has a Wall Street consensus price target of $6.00, based on estimates from 5 covering analysts. With the stock currently trading at $0.26, this represents a potential upside of +2236.4%. The company has a market capitalization of $286652.
Analyst price targets range from a low of $6.00 to a high of $6.00, representing a 0% spread in expectations. The median target of $6.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 2 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, CODX trades at a trailing P/E of -0.0x. Analysts expect EPS to grow -11.3% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 QDELQuidelOrtho Corporation | $730M | $10.70 | $12.25 | +14.5% | Hold | 13.9x | 15 |
 FLGTFulgent Genetics, Inc. | $674M | $23.74 | $19.00 | -20.0% | Buy | — | 9 |
 CLOVClover Health Investments, Corp. | $2.5B | $4.82 | $5.63 | +16.8% | Hold | 88.0x | 9 |
 NVAXNovavax, Inc. | $1.8B | $10.78 | $18.00 | +67.0% | Buy | — | 23 |
 IDXXIDEXX Laboratories, Inc. | $53.3B | $676.04 | $716.67 | +6.0% | Buy | 45.5x | 23 |
 NEOGNeogen Corporation | $2.6B | $11.76 | $13.50 | +14.8% | Buy | 35.3x | 11 |
 MESOMesoblast Limited | $1.9B | $14.27 | $39.00 | +173.3% | Buy | — | 11 |
 BNGOBionano Genomics, Inc. | $13M | $1.15 | — | — | — | — | — |
 TMOThermo Fisher Scientific Inc. | $258.2B | $694.76 | $694.27 | -0.1% | Buy | 27.5x | 43 |
 DHRDanaher Corporation | $161.9B | $230.25 | $238.77 | +3.7% | Buy | 26.8x | 43 |
Quick answers to the most common questions about buying CODX stock.
The consensus Wall Street price target for CODX is $6, representing 2236.4% upside from the current price of $0.2568. With 5 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
CODX has a consensus rating of "Hold" based on 5 Wall Street analysts. The rating breakdown is mixed, with 3 Hold ratings making up the largest segment. The consensus 12-month price target of $6 implies 2236.4% upside from current levels.
CODX's current price is $0.2568 with a consensus target of $6 (2236.4% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $6 for CODX, while the most conservative target is $6. The consensus of $6 represents the median expectation. These targets typically reflect 12-month expectations.
CODX is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CODX stock forecast based on 5 Wall Street analysts shows a consensus price target of $6, with estimates ranging from $6 (bear case) to $6 (bull case). The median consensus rating is "Hold".
Wall Street analysts are very optimistic on CODX, with a "Hold" consensus rating and $6 price target (2236.4% upside). 2 of 5 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CODX analyst price targets range from $6 to $6, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $6 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.